Document is current
Any future updates will be listed below
-
Authors
Michl, Marlies
Taverna, Francesco
Woischke, Christine
Li, Pan
Klauschen, Frederick
Kirchner, Thomas
Heinemann, Volker
von Bergwelt-Baildon, Michael
Stahler, Arndt
Herold, Tobias Marcus
Jurinovic, Vindi
Engel, Jutta
Kumbrink, Jörg https://orcid.org/0000-0003-4633-4105
Neumann, Jens
-
Funding
Funding for this research was provided by:
Ludwig-Maximilians-Universität München
- License Information
-
More Information
Article History
Received: 31 January 2024
Accepted: 11 February 2024
First Online: 17 March 2024
Declarations
:
: Within the submitted work none of all authors has a conflict of interest to declare. However, apart from the submitted work MM received honoraria for talks and advisory boards by SIRTeX, Roche, AstraZeneca, Novartis, Merck, Sanofi, Lilly and MSD, travel expenses by SIRTeX, Amgen, Sobi and Merck. AS received honoraria for Advisory Roles from BMS and NovoCure, honoraria for talks from Roche, Taiho Pharmaceutical, Servier and expenses for travel and accommodations from Roche, Merck KGaA, Amgen, Pfizer and Lilly Oncology. JN received honoraria for talks and advisory boards by Roche, Novartis, Pfizer, MSD, BMS, Falk and Pierre Fabre. VH received honoraria for talks, advisory boards and travel expenses by Merck, Amgen, Roche, Takeda, Servier, Pierre Fabre, Taiho, Lilly Oncology, Servier, Sanofi and Bayer Pharmaceuticals.
: Ethics approval and content was obtained from the local ethics committee (Approval Number 18-105). The study was conducted in accordance with the Declaration of Helsinki.
: Informed consent was obtained from all subjects involved in the study.
